Table 2 T2D patient characteristics by basal long-acting insulin analogue DET and GLAR

Total

251

47%

285

53%

Patient Characteristics

Female

101

40%

130

46%

0.2099

Male

150

60%

155

54%

Mean age

61

60

0.7123

<50 years

49

20%

63

22%

0.4629

≥50 years and <60 years

96

38%

103

36%

0.6145

≥65 years

106

42%

119

42%

0.9112

Mean weight (kilos)

86

87

0.2044

Mea height (cm)

172

172

0.4055

Mean BMI (kilos/m²)

29.1

29.8

0.3587

HbA1c value (%)

8.0 (63.9 mmol/mol)

8.2 (66.1 mmol/mol)

0.5602

Mean number of years on antdiabetic medication

11

10

0.068

Mean number of years on Determir/Glargine

2.1

2.2

0.2672

Geography

North Denmark Region

22

9%

26

9%

0.8849

Central Denmark Region

63

25%

32

11%

0.0000

Southern Denmark Region

66

26%

85

30%

0.3647

Region Sealand

43

17%

44

15%

0.5959

Capital region of Denmark

57

23%

98

34%

0.0029

Prescriber

GP

179

71%

159

56%

0.0002

Specialist

72

29%

126

44%

Concomitant insulin use

At least one product

110

44%

114

40%

0.3703

NovoRapid

79

31%

82

29%

0.4959

Actrapid

16

6%

4

1%

0.0024

Insuman Rapid

0

0%

4

1%

0.0596

Aprida

0

0%

3

1%

0.1031

Other insulin

18

7%

22

8%

0.8096

Non-insulin antdiabetic medication

At least one product

159

63%

188

66%

0.5267

Biguanides

146

58%

173

61%

0.5509

Sulfonomides

15

6%

16

6%

0.8578

Glitazoner (TZD) and combinations

0

0%

0

0%

DPP-IV inhibitors and combinations

8

3%

4

1%

0.1637

Victoza

26

10%

41

14%

0.1595

Byetta

0

0%

1

0%

0.3476